Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 10773 versus glimepiride add-on to metformin in type 2 diabetes
NL-OMON38357Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Change from baseline in HbA1c at 52 weeks and Change from baseline in HbA1c at 104 weeks. Started Dec 2010; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON38357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38357.